Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

• Has previously untreated and pathologically confirmed resectable Stage II, IIIA, orIIIB (N2) non-small cell lung cancer (NSCLC)

• Able to undergo protocol therapy, including necessary surgery

• Confirmation that epidermal growth factor receptor (EGFR) -directed therapy is notindicated as primary therapy

• Has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1as assessed within 10 days before initiation of study intervention.

• Is able to provide archival or newly obtained core/excisional biopsy of the primarylung tumor or lymph node metastasis.

Exclusion Criteria:

• Has one of the following tumor locations/types: NSCLC involving the superior sulcus,large-cell neuro-endocrine cancer, mixed tumors containing small cell and non-smallcell elements, or sarcomatoid tumor.

• Has Grade ≥2 peripheral neuropathy.

• Has history of documented severe dry eye syndrome, severe Meibomian gland diseaseand/or blepharitis, or severe corneal disease that prevents/delays corneal healing.

• Has active inflammatory bowel disease requiring immunosuppressive medication orprevious history of inflammatory bowel disease (eg, Crohn's disease, ulcerativecolitis, or chronic diarrhea).

• Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.

• Received a live or live-attenuated vaccine within 30 days before the first dose ofstudy intervention

• Received prior radiotherapy within 2 weeks of start of study intervention, orradiation related toxicities, requiring corticosteroids.

• Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (indosing exceeding 10 mg daily of prednisone equivalent) or any other form ofimmunosuppressive therapy within 7 days prior to the first dose of studyintervention.

• Known additional malignancy that is progressing or has required active treatmentwithin the past 5 years.

• Severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.

• Active autoimmune disease that has required systemic treatment in the past 2 years.Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid) isallowed.

• History of (noninfectious) pneumonitis/interstitial lung disease that requiredsteroids or has current pneumonitis/interstitial lung disease.

• Active infection requiring systemic therapy.

• Hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or Hepatitis Cvirus (defined as detectable hepatitis C virus (HCV) ribonucleic acid (RNA) [qualitative]) infection.

• Known history of human immunodeficiency virus (HIV) infection.

• History of allogeneic tissue/solid organ transplant.